New hope for ovarian cancer: drug combo targets relapsed patients

NCT ID NCT07370818

Not yet recruiting Disease control Sponsor: Onconic Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests a new drug called JPI-547 combined with bevacizumab in 81 women with relapsed ovarian cancer who have already been treated with PARP inhibitors and responded to platinum chemotherapy. The study aims to find the best dose and see if the combination helps keep the cancer from growing longer. It is not yet recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JPI-547 (a drug) combined with bevacizumab (another drug)
What this could lead to: If successful, this could offer a new maintenance treatment option for relapsed ovarian cancer patients who have already tried PARP inhibitors.
What could go wrong: This is an early Phase 2 trial with only 81 participants, so results may not apply to all patients. The drug may not improve survival or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer ovarian cancer primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER

Contacts and locations

Locations

Severance Hospital, Yonsei Cancer Center, Yonsei University College of Medicine

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.